Bloomberg | Free-Spending Private Equity Firms Set Record Pace in Europe

Feb 2021

Originally published by Bloomberg on February 14, 2021.

Phil McCreanor, Managing Director and Head of Investment Banking, UK & Nordics, discusses with Bloomberg his perspective on COVID-19’s effect on private equity dealmaking on the year ahead. Click here to view the full article.

Summary

  • Phil McCreanor, Managing Director and Head of Investment Banking, UK & Nordics, discusses with Bloomberg the opportunities emerging from COVID-19 for private equity dealmaking in Europe in 2021.

  • Sign up to receive Lincoln's perspectives

Contributor

Meet Our Senior Team in M&A

Related Perspectives

Cybersecurity Report: Q3 2022

Q3 2022 cyber mergers and acquisitions (M&A) continue to demonstrate relative buoyancy. Year-to-date (YTD) Q3 2022 cybersecurity M&A volume of $25 billion, while a decline compared to 2021’s record of $49… Read More

In Vivo Pharma Intelligence | The Growth Path for Drug Discovery Partners

Originally published by In Vivo Pharma Intelligence on November 15, 2022 James West, Director in Lincoln’s Healthcare Group, explains the key trends and mergers and acquisitions (M&A) dynamics in the… Read More

Specialty Chemicals: The Story of the Specialty Transformation

The specialty chemicals equity story is becoming increasingly important as the historical diversification benefit of more traditional commodity chemicals players – or even the diversified chemical conglomerates of yore –… Read More

The Hidden Gem in European Pet Food: European Investors Spot New Opportunity in Raw & Gently Cooked Pet Food

European investors are capitalizing on the fastest growing segment of the European pet food category, powered by pet owners’ ongoing desire for higher quality and natural food options for their… Read More